Trademark: 87329452
Word
BIOHAVEN
Status
Registered
Status Code
700
Status Date
Tuesday, August 18, 2020
Serial Number
87329452
Registration Number
6130617
Registration Date
Tuesday, August 18, 2020
Mark Type
4000
Filing Date
Wednesday, February 8, 2017
Published for Opposition
Tuesday, March 6, 2018

Trademark Owner History

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use

Trademark Events
Apr 17, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 17, 2023
Teas Change Of Correspondence Received
Apr 17, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 17, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 17, 2023
Teas Change Of Owner Address Received
Jan 11, 2023
Automatic Update Of Assignment Of Ownership
Jun 21, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 21, 2021
Teas Change Of Correspondence Received
Jun 21, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 21, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 21, 2021
Teas Change Of Owner Address Received
Aug 26, 2020
Assignment Of Ownership Not Updated Automatically
Aug 18, 2020
Registered-Principal Register
Jul 16, 2020
Notice Of Acceptance Of Statement Of Use E-Mailed
Jul 15, 2020
Allowed Principal Register - Sou Accepted
Jun 25, 2020
Statement Of Use Processing Complete
Jun 23, 2020
Use Amendment Filed
Jun 23, 2020
Teas Statement Of Use Received
May 14, 2020
Notice Of Approval Of Extension Request E-Mailed
May 13, 2020
Sou Extension 4 Granted
May 1, 2020
Sou Extension 4 Filed
May 13, 2020
Case Assigned To Intent To Use Paralegal
May 1, 2020
Sou Teas Extension Received
Feb 3, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 3, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 13, 2020
Withdrawal Of Attorney Granted
Jan 13, 2020
Teas Withdrawal Of Attorney Received
Oct 25, 2019
Notice Of Approval Of Extension Request E-Mailed
Oct 23, 2019
Sou Extension 3 Granted
Oct 23, 2019
Sou Extension 3 Filed
Oct 23, 2019
Sou Teas Extension Received
Oct 23, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 23, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 26, 2019
Notice Of Approval Of Extension Request E-Mailed
Apr 24, 2019
Sou Extension 2 Granted
Apr 24, 2019
Sou Extension 2 Filed
Apr 24, 2019
Sou Teas Extension Received
Sep 12, 2018
Notice Of Approval Of Extension Request E-Mailed
Sep 10, 2018
Sou Extension 1 Granted
Sep 10, 2018
Sou Extension 1 Filed
Sep 10, 2018
Sou Teas Extension Received
May 1, 2018
Noa E-Mailed - Sou Required From Applicant
Mar 6, 2018
Official Gazette Publication Confirmation E-Mailed
Mar 6, 2018
Published For Opposition
Feb 14, 2018
Notification Of Notice Of Publication E-Mailed
Feb 1, 2018
Approved For Pub - Principal Register
Jan 30, 2018
Teas/Email Correspondence Entered
Jan 30, 2018
Correspondence Received In Law Office
Jan 26, 2018
Assigned To Lie
Jan 16, 2018
Teas Request For Reconsideration Received
Jan 8, 2018
Notification Of Final Refusal Emailed
Jan 8, 2018
Final Refusal E-Mailed
Jan 8, 2018
Final Refusal Written
Dec 15, 2017
Teas/Email Correspondence Entered
Dec 14, 2017
Correspondence Received In Law Office
Dec 14, 2017
Teas Response To Office Action Received
Jun 21, 2017
Notification Of Non-Final Action E-Mailed
Jun 21, 2017
Non-Final Action E-Mailed
Jun 21, 2017
Non-Final Action Written
May 9, 2017
Notification Of Non-Final Action E-Mailed
May 9, 2017
Non-Final Action E-Mailed
May 9, 2017
Non-Final Action Written
May 3, 2017
Assigned To Examiner
Feb 14, 2017
New Application Office Supplied Data Entered
Feb 13, 2017
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24